In August the company was accepted into the AMPlify program (an accelerated market entry platform), which is organized in collaboration with Mayo Clinic (USA) and Business Finland. The program supports the commercialization projects of the company’s ovarian cancer test currently under development. Our… Read More
Kaisa Huhtinen, Uniogen´s Oncology Clinical Manager, has a deep understanding of ovarian cancer diagnostics as a PhD and an Associate Professor. Kaisa is participating in the European Society of Medical Oncology (ESMO)– congress held in Barcelona the 13th – 17… Read More
Uniogen’s commitment to environmental, social, and governance (ESG) principles has never been stronger, as demonstrated in our 2023 Sustainability report. We caught up with Maija Jortikka, our Sustainability Specialist, to discuss this year’s highlights and the impactful changes Uniogen is implementing. Embracing a robust Code of Conduct Maija begins… Read More
April was an exciting month for Uniogen, filled with significant participation at three major global congresses that align closely with our mission and expertise. We are thrilled to share key insights and developments from these events, reinforcing our commitment to innovation and collaboration in the fields of clinical diagnostics… Read More
Upcon™ upconverting nanoparticle (UCNP) system is breaking new ground in the world of diagnostics. This advanced detection technology utilizes photon upconversion to enhance lateral flow assays, making it a game-changer for diagnostic accuracy and performance. Why choose Upcon? The Upcon system is not just another diagnostic tool—it’s a comprehensive solution… Read More
Uniogen has been featured in Finland’s national public broadcasting company news for developing… Read More
As spring blooms, Uniogen is gearing up for a dynamic April, packed with participation in three significant events: UPCON 2024 in Montréal, Analytica 2024 in Munich, and ECCMID 2024 in Barcelona. First, we are excited to attend the UPCON 2024 conference with our own booth, starting on April 7… Read More
Antti-Heikki Tapio, a member of Uniogen’s R&D team, shares his inspiring journey in biotechnology and the background of the GenomEra GBS Assay Kit. Antti-Heikki started studying at Turku University of Applied Sciences in 2002 and continued his studies at… Read More
Uniogen has been selected to participate in a climate program led by The Finland Chamber of Commerce and supported by LähiTapiola, representing a significant advancement in environmental responsibility for small and medium-sized businesses. This participation reflects a growing commitment to engage in climate action. The program equips participating companies with… Read More
Uniogen’s cancer diagnostic platform is based on research conducted and published at the University of Turku. Studies show that the concept of glycosylation-specific immunoassays is clearly superior to currently used blood-based markers in cancer diagnosis and monitoring. See the… Read More
